IL2 and neoplasm: In an attempt to identify predictive factors for objective response and prognostic factors for survival, we have monitored lymphocyte subsets in as well consecutive peripheral blood samples as consecutive tumour tissue core needle biopsies in patients with mRCC undergoing immunotherapy with IL-2, IFN-α and histamine.